<qa>  What is a single arm, open-label, phase II study to assess pathologicThis is a single arm, open-label, phase II study to assess pathologic objective response rate complete response partial response in patients treated with pembrolizumab, paclitaxel and carboplatin for advanced stage III or IV Ovarian, Fallopian Tube, or Peritoneal Carcinoma EOC. 